Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland

Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictions, dysphoria related to life-threatening illnesses and depression. Research suggests that the mystical experience (ME) under psychedelics appears to play a key role in positive outcomes. With a growing evidence base, it is possible that PAP may be available in the National Health Service in the near future. As such, the current case study explored the following research question: What are the attitudes towards the potential therapeutic benefits and potential risks of the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland? Semi-structured interviews were conducted with five core psychiatry trainees. Through thematic analysis of interview material four main themes emerged: General Knowledge About the Mystical Experience; Openness to Psychedelic Assisted Psychotherapy; Implications for Psychiatry; and Concerns. The collective case summary suggests that the group were open to the introduction of PAP in psychiatry and to the potential therapeutic value of the ME, however a biomedical focus in keeping with the prevailing medical model was apparent. Trainees also recognised the need for training in its delivery. The findings were explored in relation to relevant literature regarding PAP and transpersonal aspects of the ME which may occur as a result. As PAP gains credibility a holistic approach integrating the understandings of modern psychiatry with transpersonal aspects may be of value.